Please log in
You must be logged in to send the contact request.
Manage stand orders
Select Option
BrosMed Medical Co., Ltd.
3F, 15th Building, SMES Venture Park Songshan Lake Hi-tech Zone,
523808
Dongguan, Guangdong
China
China
Submit your contact details
Provide your contact details to the exhibitor. Optionally, you may also add a personal message.
Your name, phone number, and e-mail address are subject to the submission of personal data. Messe Düsseldorf GmbH expressly points out that for a data transmission into third countries, for which no adequacy decision of the EU-commission is on hand certifying an adequate level of protection of personal data, it is not ensured that there are appropriate safeguards for the protection of personal data on hand.
An error has occurred
Please check your internet connection or try again later.
Message has been sent
Your message to the exhibitor was sent successfully.
Contact
Visit us
16.11.2020
Topic
all-day
Ideal choice for Arteriovenous Fistula (AV) Shunt Scoring
Tri-Wedge PTA Scoring Balloon Dilatation Catheter achieves accurate annular fibrous, calcified plaque location and minimal balloon slippage. This balloon with trimetallic wires can reach lesions smoothly with an uniform vertical distribution. High efficient vertical extrusion to score the plaque with concentrated dilatation stress, low pressure and high safety dilatation reduces the vessel wall injury and incidence of restenosis.
Tri-Wedge Peripheral balloon provides excellent crossing ability, high pressure and non-compliance. It was ideally designed in the treatment of complex lesions with significant calcification and fibrosis. It is believed this unique balloon design technology will make a difference to the PTA scoring balloon market.
Tri-Wedge Peripheral balloon provides excellent crossing ability, high pressure and non-compliance. It was ideally designed in the treatment of complex lesions with significant calcification and fibrosis. It is believed this unique balloon design technology will make a difference to the PTA scoring balloon market.
Our range of products
Product categories
- 01 Electromedical equipment / medical technology
- 01.03 Surgery devices, endoscopy devices
- 01.03.01 Vascular surgical instruments, accessories
Vascular surgical instruments, accessories
- PTCA—Alveo φ0.75mm High Pressure Balloon Catheter
- PTCA—Artimes Balloon Dilatation Catheter
- PTCA—Apollo Balloon Dilatation Catheter
- PTCA—Wedge Semi-Compliant Scoring PTCA Balloon Catheter
- PTCA—Wedge Non-Compliant Scoring PTCA Balloon Catheter
- PTA—Tri-Wedge PTA Scoring Balloon Dilatation Catheter
- PTA—Polux Semi-Compliant 0.014 OTW PTA Balloon Dilatation Catheter
- PTA—Castor Non-Compliant 0.014 OTW PTA Balloon Dilatation Catheter
- PTA—Minerva Semi-Compliant 0.018 OTW PTA Balloon Dilatation Catheter
- PTA —Achilles Non-Compliant 0.018 OTW PTA Balloon Dilatation Catheter
- PTA—Atropos Semi-Compliant 0.035 OTW PTA Balloon Dilatation Catheter
- PTA—Hermes Non-Compliant 0.035 OTW PTA Balloon Dilatation Catheter
- Interventional Accessories—Conger™ Hydrophilic Guidewire
- Interventional Accessories—Y Connector Sets
- Interventional Accessories—Balloon Inflation Devices
- Interventional Accessories—Non-vascular Guide Wires
- Interventional Accessories—Introducer Sheath Sets
- Interventional Accessories—Manifolds
- Interventional Accessories—Radial Artery Tourniquets
- Interventional Accessories—Dose-control Syringes
- Interventional Accessories—Introducer Needles
- Interventional Accessories—Connecting Tubings
- Interventional Accessories—Angiographic Syringes
- Interventional Accessories—Angiographic Accessories
- Interventional Accessories—FreePath™ Catheter Sheath Introducer
- 01 Electromedical equipment / medical technology
- 01.03 Surgery devices, endoscopy devices
- 01.03.02 Instruments for the minimal-invasive surgery (MIS)
Instruments for the minimal-invasive surgery (MIS)
- 01 Electromedical equipment / medical technology
- 01.03 Surgery devices, endoscopy devices
- 01.03.05 Instruments and apparatus for cardiac and thoracic surgery
Instruments and apparatus for cardiac and thoracic surgery
Our products
Product category: Vascular surgical instruments, accessories
PTCA—Alveo φ0.75mm High Pressure Balloon Catheter
With 0.75 mm in diameter Alveo HP is the smallest high pressure CTO balloon catheter in the world.
Alveo HP is specifically designed for crossing complex lesions and Chronic Total Occlusions (CTO) as well as tracking tortuous anatomy.
Alveo HP is specifically designed for crossing complex lesions and Chronic Total Occlusions (CTO) as well as tracking tortuous anatomy.
- Proprietary balanced distal tip technology;
- Proprietary distal laser welding technology eliminates hardness and maintains distal tip flexibility;
- No transition in the distal laser welding resulting in smallest crossing profile;
- Enhanced shaft design.
Product category: Vascular surgical instruments, accessories
PTCA—Apollo Balloon Dilatation Catheter
Apollo is a non-compliant high pressure post-dilatation catheter offering numerous features for enhanced and robust performance.
- Exceptionally minimal axial growth during inflation;
- 5F guiding catheter compatible;
- Versatile balloon diameters and lengths to meet clinical demands;
- Average balloon burst pressure is 30 atm.
Product category: Vascular surgical instruments, accessories
PTCA—Wedge Semi-Compliant Scoring PTCA Balloon Catheter
Wedge SC Scoring PTCA is the world smallest scoring balloon catheter which ideal for small vessel and specialty for Hard/Calcified lesion.
- Suitable for Diffuse Lesion;
- Maximally Eliminating Dissection;
- Minimal Slippage.
Product category: Vascular surgical instruments, accessories
PTCA—Wedge Non-Compliant Scoring PTCA Balloon Catheter
With one fixed nitinol wire on top of the balloon surface, Wedge NC provides exact scoring and avoids twisted wires or interference with the stent.
- Reduces "dog-boning" effect;
- Minimizes "watermelon seeding" ;
- Creates a controlled dissection;
- Creates larger diameter than a regular balloon.
Product category: Vascular surgical instruments, accessories
PTA—Tri-Wedge PTA Scoring Balloon Dilatation Catheter
Tri-Wedge is designed for precise dilatation specifically in dysfunctional arteriovenous fistula and grafts (AVF and AVG).
- Three triangular designed metallic scoring elements;
- Effective slippage elimination during inflation;
- Higher RBP up to 20atm.
Product category: Vascular surgical instruments, accessories
PTA —Achilles Non-Compliant 0.018 OTW PTA Balloon Dilatation Catheter
Excellent for high pressure dilatation and lesion preparation
- Combination of strength and optimal control in routine and challenging cases;
- Broad range of sizes available;
- Confident to treat all lower extremity lesions.
Product category: Vascular surgical instruments, accessories
PTA—Atropos Semi-Compliant 0.035 OTW PTA Balloon Dilatation Catheter
Engineered for AV access
- Combines strength and optimal control in routine and challenging cases;
- Designed to treat fibrotic and calcified lesions;
- Broad size range: Diameter: 3.0 - 10.0mm ，Length: 20 - 200mm.
Product category: Vascular surgical instruments, accessories
PTA—Hermes Non-Compliant 0.035 OTW PTA Balloon Dilatation Catheter
Engineered for AV access
- Combination of strength and optimal control in routine and challenging cases;
- Designed to treat fibrotic and calcified lesions;
- Broad size range: Diameter: 3.0 - 10.0mm，Length: 20 - 150mm.
Product category: Vascular surgical instruments, accessories
Interventional Accessories—Conger™ Hydrophilic Guidewire
• One-piece nitinol core construction promotes pushability and easy advancement;
• One to one torque for navigating distal and angulated branch vessels;
• Durable hydrophilic coating to facilitate crossing of tight lesions;
• Stiff and standard versions accommodate a wide range of clinical applications.
• One to one torque for navigating distal and angulated branch vessels;
• Durable hydrophilic coating to facilitate crossing of tight lesions;
• Stiff and standard versions accommodate a wide range of clinical applications.
Product category: Vascular surgical instruments, accessories
Interventional Accessories—Non-vascular Guide Wires
Good maneuverability, flexibility, visibility, traceability, smoothness and support.
- Teflon coating provides excellent crossability for other interventional devices and protects against thrombus formation;
- Customized diameters and lengths are available.
Product category: Vascular surgical instruments, accessories
Interventional Accessories—Introducer Sheath Sets
- The sheath offers excellent kink resistance and flexibility with smooth transitions between cannula, dilator and guide wire;
- Smooth tapered tip results in low insertion force, avoids wrinkling and reduces puncture site trauma;
- Advanced engineering and special design of hemostatic valve maintains good hemostasis and facilitates smooth operation for guide wire and catheter.
Product category: Vascular surgical instruments, accessories
Interventional Accessories—Radial Artery Tourniquets
- The device is used to achieve hemostasis after the radial arterial catheterization;
- Unique design for radial artery hemostasis post percutaneous puncture;
- Transparent fixed plates ensures clear visual control;
- Soft and comfortable adjustable band.
Product category: Vascular surgical instruments, accessories
Interventional Accessories—Dose-control Syringes
- Easy to operate with one hand;
- Clear scale and accurate measurement of infusion volume;
- Provides exceptional clarity and smooth as glass feel;
- Intended to minimize the potential of air bubbles introduced into the catheter.
Product category: Vascular surgical instruments, accessories
Interventional Accessories—Angiographic Accessories
- Good sealing of plunger ,unique push button ,clear scale make easy to operate and control；
- Diverse capacity: more accurate operation, more convenient clinical use；
- Transparent material makes the flow visible；
- Great Variety of angiographic syringes and accessories to choose.
Company news
Date
Topic
Download
Nov 12, 2020
WEDGES CLINICAL INVESTIGATION PLAN IN BELGIUM
WEDGES:
A prospective, multi-center randomized trial for the evaluation of coronary lesion preparation:
an assessment of a new scoring balloon by quantitative stent enhanced visualization
Sittard, the Netherlands, November 13, 2020 – Brosmed Medical, a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Belgium have been enrolled in the Wedges study, a multi-center randomized trial for the evaluation of coronary lesion preparation with enhanced dilatation for the good expansion of stent: assessment of a new scoring balloon by quantitative enhanced visualization.
The Wedge is a scoring balloon dilatation catheter that comes in a non-compliant as well as a semi-compliant version for safe and controlled lesion preparation.
Dr. Stephane Carlier, head of the Cardiology Department at CHU Ambroise Pare & UMONS – Mons, Belgium, where the first patients in Belgium will be treated, said, Brosmed Medical´s new scoring catheter technology allows physicians to gently modify calcified plaque and enables coronary revascularization for patients with calcified arteries in a more controlled manner. The introduction of the Wedge in Belgium greatly improves the treatment options for my patients suffering from coronary artery disease, or CAD.
About Brosmed Medical
BrosMed is a high-value medical device manufacturer specializing in the design, production, and sales of vascular interventional medical devices. At present, BrosMed global product line covers cardiovascular interventions, peripheral vascular interventions and a full set of interventional accessories.
A prospective, multi-center randomized trial for the evaluation of coronary lesion preparation:
an assessment of a new scoring balloon by quantitative stent enhanced visualization
Sittard, the Netherlands, November 13, 2020 – Brosmed Medical, a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in Belgium have been enrolled in the Wedges study, a multi-center randomized trial for the evaluation of coronary lesion preparation with enhanced dilatation for the good expansion of stent: assessment of a new scoring balloon by quantitative enhanced visualization.
The Wedge is a scoring balloon dilatation catheter that comes in a non-compliant as well as a semi-compliant version for safe and controlled lesion preparation.
Dr. Stephane Carlier, head of the Cardiology Department at CHU Ambroise Pare & UMONS – Mons, Belgium, where the first patients in Belgium will be treated, said, Brosmed Medical´s new scoring catheter technology allows physicians to gently modify calcified plaque and enables coronary revascularization for patients with calcified arteries in a more controlled manner. The introduction of the Wedge in Belgium greatly improves the treatment options for my patients suffering from coronary artery disease, or CAD.
About Brosmed Medical
BrosMed is a high-value medical device manufacturer specializing in the design, production, and sales of vascular interventional medical devices. At present, BrosMed global product line covers cardiovascular interventions, peripheral vascular interventions and a full set of interventional accessories.
Nov 12, 2020
Clinical Trial of Tri-Wedge PTA Scoring Balloon Dilatation Catheter
Tri-Wedge PTA Scoring Balloon Dilatation Catheter (hereinafter referred to as Tri-Wedge), manufactured by Brosmed Medical Co., Ltd., is an “over-the wire” catheter with a unique feature that three stainless steel wires (triangular cross-section) are evenly distributed on the outer surface of the balloon, which creates a focal stress pattern to dilate the stenotic lesion at lower pressure. The technology has been applied for international and Chinese patents. The product is indicated to dilate the stenosis in the iliac, femoral, iliofemoral arteries, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.
Tri-Wedge can achieve the same luminal gain with lower inflation pressure and minimal slippage because of three scoring stainless steels, also possesses soft tip, extraordinary crossability, and smaller profile size for passing through severely calcified stenotic lesions. The catheter is the unique product on the market targeted at arteriovenous fistula stenosis. It has been approved for listing in the EU and Singapore.
As shown in the PDF, the balloon is available in a wide range of sizes.
A clinical study led by Peking University First Hospital to evaluate the safety and efficacy of Tri-Wedge for Treatment of Dysfunctional AV Fistula (referred to as Tri-Wedge clinical trial) started on June 9th, 2020. Prof. Jin Qizhuang’s team which successfully performed the first case, applying the Tri-Wedge to treat arteriovenous fistula stenosis in hemodialysis patient. The successful implementation of the procedure also marks the official launch of multi-center Tri-Wedge clinical trial nationwide. Six nationally renowned clinical centers participate in the trial. The procedure will be conducted by experienced clinical experts, with their exquisite medical skills and well-designed equipment, the trial would complete as expectation with no doubt and introduce a groundbreaking product to the Chinese market.
Until November 5th,2020, Tri-Wedge clinical trial has successfully enrolled 47 subjects, completed follow-up in 12 cases, with no device-related adverse events or device defects, revealing good therapeutic effect.
A subject by Peking Tong Ren Hospital has a target vessel with a diameter of 5 mm and a length of 24 mm. The physicians chose Tri-Wedge size of 5.0 mm ×40 mm, and the balloon sufficiently dilated under an inflation pressure of 4 atm. To consolidate the effect, the catheter continued to be inflated to 12 atm. The residual stenosis was measured after the operation, showing a result of 5% under post-operation DSA, 10.53% under DUS, revealing great success of the procedure. This case adequately demonstrated that the Tri-Wedge can sufficiently dilate the stenotic lesion under a low inflation pressure.
This clinical study would provide sufficient evidence for the safety and efficacy of the Tri-Wedge in the treatment of autologous arteriovenous fistula stenosis, bringing good news to hemodialysis patients.
Tri-Wedge can achieve the same luminal gain with lower inflation pressure and minimal slippage because of three scoring stainless steels, also possesses soft tip, extraordinary crossability, and smaller profile size for passing through severely calcified stenotic lesions. The catheter is the unique product on the market targeted at arteriovenous fistula stenosis. It has been approved for listing in the EU and Singapore.
As shown in the PDF, the balloon is available in a wide range of sizes.
A clinical study led by Peking University First Hospital to evaluate the safety and efficacy of Tri-Wedge for Treatment of Dysfunctional AV Fistula (referred to as Tri-Wedge clinical trial) started on June 9th, 2020. Prof. Jin Qizhuang’s team which successfully performed the first case, applying the Tri-Wedge to treat arteriovenous fistula stenosis in hemodialysis patient. The successful implementation of the procedure also marks the official launch of multi-center Tri-Wedge clinical trial nationwide. Six nationally renowned clinical centers participate in the trial. The procedure will be conducted by experienced clinical experts, with their exquisite medical skills and well-designed equipment, the trial would complete as expectation with no doubt and introduce a groundbreaking product to the Chinese market.
Until November 5th,2020, Tri-Wedge clinical trial has successfully enrolled 47 subjects, completed follow-up in 12 cases, with no device-related adverse events or device defects, revealing good therapeutic effect.
A subject by Peking Tong Ren Hospital has a target vessel with a diameter of 5 mm and a length of 24 mm. The physicians chose Tri-Wedge size of 5.0 mm ×40 mm, and the balloon sufficiently dilated under an inflation pressure of 4 atm. To consolidate the effect, the catheter continued to be inflated to 12 atm. The residual stenosis was measured after the operation, showing a result of 5% under post-operation DSA, 10.53% under DUS, revealing great success of the procedure. This case adequately demonstrated that the Tri-Wedge can sufficiently dilate the stenotic lesion under a low inflation pressure.
This clinical study would provide sufficient evidence for the safety and efficacy of the Tri-Wedge in the treatment of autologous arteriovenous fistula stenosis, bringing good news to hemodialysis patients.
Apr 28, 2018
Memorabilia of BrosMed Medical FDA 510(k) Clearance and PMDA Approval
It took fewer than five years for Brosmed to distribute products over 40 countries and regions. So far, BrosMed is the only Chinese brand that provides high-end medical devices in the US, Japan and EU areas.
Timeline of BrosMed Medical FDA 510(k) Clearance and PMDA Approval in Global Market：
1. In July 16, 2013, BrosMed Received FDA Initial Registration for Facility Establishment.
2. In September 17, 2014, BrosMed Announces FDA 510(k) Clearance and Launch for Artimes™ Balloon Dilatation Catheter in the North America and Global Market.
3. In October 8, 2014, BrosMed Announces FDA 510(k) Clearance and Launch for Apollo™ Balloon Dilatation Catheter in the North America and Global Market.
4. In August 3rd, 2016, BrosMed Announces FDA 510(k) Clearance and Launch of Atropos™ 0.035 OTW PTA, Minerva™ 0.018 OTW PTA and Polux™ 0.014 OTW PTA Balloon Dilatation Catheters.
5. In August 8th, 2016, BrosMed Announces FDA 510(k) Clearance and Launch of Additonal Configurations Apollo™ NC PTCA Balloon Catheters in Unitied States and North Amercia Market.
6. In December 14, 2016, BrosMed Announces FDA 510(k) Clearance and Launch of Hermes™ NC 0.035 OTW PTA, Achilles™ NC 0.018 OTW PTA and Castor™ NC 0.014 OTW PTA Balloon Dilatation Catheters.
7. In Aug 30th , 2017, BrosMed Medical Announces PMDA Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market. These two balloons are designed for the treatment of percutaneous transluminal coronary angioplasty (PTCA) for the purpose of improving myocardial blood flow in the localized stenotic lesion of the coronary arteries. Following the approval, BrosMed Medical achieves one more step to its global vision beside current geographical footprint in Europe, USA, China, Asia Pacific, Latin America and Middle East.
8. In April 28th, 2018, BrosMed Medical Announces Completes Successful FDA Inspection. This comes as a result of Brosmed medical 5 years ongoing commitment to the highest levels of quality standards.
Timeline of BrosMed Medical FDA 510(k) Clearance and PMDA Approval in Global Market：
1. In July 16, 2013, BrosMed Received FDA Initial Registration for Facility Establishment.
2. In September 17, 2014, BrosMed Announces FDA 510(k) Clearance and Launch for Artimes™ Balloon Dilatation Catheter in the North America and Global Market.
3. In October 8, 2014, BrosMed Announces FDA 510(k) Clearance and Launch for Apollo™ Balloon Dilatation Catheter in the North America and Global Market.
4. In August 3rd, 2016, BrosMed Announces FDA 510(k) Clearance and Launch of Atropos™ 0.035 OTW PTA, Minerva™ 0.018 OTW PTA and Polux™ 0.014 OTW PTA Balloon Dilatation Catheters.
5. In August 8th, 2016, BrosMed Announces FDA 510(k) Clearance and Launch of Additonal Configurations Apollo™ NC PTCA Balloon Catheters in Unitied States and North Amercia Market.
6. In December 14, 2016, BrosMed Announces FDA 510(k) Clearance and Launch of Hermes™ NC 0.035 OTW PTA, Achilles™ NC 0.018 OTW PTA and Castor™ NC 0.014 OTW PTA Balloon Dilatation Catheters.
7. In Aug 30th , 2017, BrosMed Medical Announces PMDA Approval and Launch of Artimes™ and Apollo™ PTCA In Japan Market. These two balloons are designed for the treatment of percutaneous transluminal coronary angioplasty (PTCA) for the purpose of improving myocardial blood flow in the localized stenotic lesion of the coronary arteries. Following the approval, BrosMed Medical achieves one more step to its global vision beside current geographical footprint in Europe, USA, China, Asia Pacific, Latin America and Middle East.
8. In April 28th, 2018, BrosMed Medical Announces Completes Successful FDA Inspection. This comes as a result of Brosmed medical 5 years ongoing commitment to the highest levels of quality standards.
- BrosMed Announces FDA 510(k) Clearance for Artimes™ Balloon Dilatation Catheter
- BrosMed Announces FDA 510(k) Clearance for Apollo™ Balloon Dilatation Catheter
- BrosMed Announces PMDA Approval for Artimes™ & Apollo™ Balloon Dilatation Catheter
- BrosMed Announces Completes Successful FDA Inspection
- BrosMed Announces FDA 510(k) Clearance and Launch of PTA NC Balloon Dilatation Catheter
Mar 31, 2017
BrosMed Announces Strategic Agreement with Cardinal Health
March 31st, 2017 in CIT 2017 Beijing China — BrosMed announced that it has entered into a strategic distribution agreement with Cardinal Health.
Through this distribution agreement, BrosMed Medical will significantly increase the market share and penetration of its leading family of percutaneous transluminal coronary angioplasty (PTCA) which includes Artimes™ Semi-Compliant and Apollo™ Non-Compliant coronary balloon dilatation catheters.
The agreement will initially enable Cordis, Cardinal Health’s interventional vascular business, to distribute BrosMed’s brand PTCA balloon dilatation catheter in mainland China. Both Artimes™ and Apollo™ products which have obtained CFDA and CE approval and FDA clearance are manufactured in China and being sold globally.
“The agreement between BrosMed Medical and Cardinal Health is an extremely important milestone in our continuing strategy to deepen our market penetration and expand as well as diversify our products offering and service” said Benny Lee, Chairman of BrosMed Medical. “Working together with Cardinal Health shall be able to leverage our joint capabilities of delivering state-of-art products including Artimes™ and Apollo™ PTCA, while maximizing the increased market coverage in the Mainland China through geographical footprint of BrosMed Medical and Cordis franchises.”
“Our PTCA portfolio covers semi-compliant, non-compliant and CTO 1.0mm balloon catheters, the products are being sold in thirty (30) countries and territories, including USA , China and EU, those are well received in the market and acknowledged by top key opinion leader (KOL). BrosMed dedicate ourselves to the new products and technology in order to consistently provide high quality products and services to the cardiovascular and endovascular patients around the world.” said Stephen Lee, General Manager of BrosMed Medical.
Through this distribution agreement, BrosMed Medical will significantly increase the market share and penetration of its leading family of percutaneous transluminal coronary angioplasty (PTCA) which includes Artimes™ Semi-Compliant and Apollo™ Non-Compliant coronary balloon dilatation catheters.
The agreement will initially enable Cordis, Cardinal Health’s interventional vascular business, to distribute BrosMed’s brand PTCA balloon dilatation catheter in mainland China. Both Artimes™ and Apollo™ products which have obtained CFDA and CE approval and FDA clearance are manufactured in China and being sold globally.
“The agreement between BrosMed Medical and Cardinal Health is an extremely important milestone in our continuing strategy to deepen our market penetration and expand as well as diversify our products offering and service” said Benny Lee, Chairman of BrosMed Medical. “Working together with Cardinal Health shall be able to leverage our joint capabilities of delivering state-of-art products including Artimes™ and Apollo™ PTCA, while maximizing the increased market coverage in the Mainland China through geographical footprint of BrosMed Medical and Cordis franchises.”
“Our PTCA portfolio covers semi-compliant, non-compliant and CTO 1.0mm balloon catheters, the products are being sold in thirty (30) countries and territories, including USA , China and EU, those are well received in the market and acknowledged by top key opinion leader (KOL). BrosMed dedicate ourselves to the new products and technology in order to consistently provide high quality products and services to the cardiovascular and endovascular patients around the world.” said Stephen Lee, General Manager of BrosMed Medical.
About us
Company details
Established in March 2012, BrosMed is a high-value medical device manufacturer specializing in the design, production, and sales of vascular interventional medical devices.
BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution. To make it simpler, to make it better, to make it more cost efficient, and to make it with excellent quality. To expand treatment options for clinicians by overcoming traditional barriers. To enhance patient freedom and fulfillment.
Mission Statement
“Inventing a movement, improving lives and inspiring everyone (invent, improve and inspire).”
We are not working alone. Part of our success has come through working closely with customers, patients, industry and institute partners, and government leaders and agencies to realize the vision of better, simpler and more accessible healthcare.
Our ultimate purpose is to improve the lives of patients, and our approach is already resulting in changed lives and industry improvements. Together, we’re changing traditional perceptions of how health care can be delivered.
BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.
We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.
At present, BrosMed global product line covers cardiovascular interventions, peripheral vascular interventions and a full set of interventional accessories.
PTCA Balloon Dilatation Catheter:
BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution. To make it simpler, to make it better, to make it more cost efficient, and to make it with excellent quality. To expand treatment options for clinicians by overcoming traditional barriers. To enhance patient freedom and fulfillment.
Mission Statement
“Inventing a movement, improving lives and inspiring everyone (invent, improve and inspire).”
We are not working alone. Part of our success has come through working closely with customers, patients, industry and institute partners, and government leaders and agencies to realize the vision of better, simpler and more accessible healthcare.
Our ultimate purpose is to improve the lives of patients, and our approach is already resulting in changed lives and industry improvements. Together, we’re changing traditional perceptions of how health care can be delivered.
BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.
We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.
At present, BrosMed global product line covers cardiovascular interventions, peripheral vascular interventions and a full set of interventional accessories.
PTCA Balloon Dilatation Catheter:
- Alveo φ0.75mm High Pressure Balloon Catheter；
- Wedge Semi-Compliant Scoring PTCA Balloon Catheter；
- Wedge Non-Compliant Scoring PTCA Balloon Catheter；
- Artimes Balloon Dilatation Catheter；
- Apollo Balloon Dilatation Catheter.
- Tri-Wedge PTA Scoring Balloon Dilatation Catheter;
- Polux Semi-Compliant 0.014 OTW PTA Balloon Dilatation Catheter;
- Castor Non-Compliant 0.014 OTW PTA Balloon Dilatation Catheter;
- Minerva Semi-Compliant 0.018 OTW PTA Balloon Dilatation Catheter;
- Achilles Non-Compliant 0.018 OTW PTA Balloon Dilatation Catheter;
- Atropos Semi-Compliant 0.035 OTW PTA Balloon Dilatation Catheter;
- Hermes Non-Compliant 0.035 OTW PTA Balloon Dilatation Catheter.
- Angiographic Syringes-Contrast media syringes for CT/DSA/MRI;
- Introducer sheath sets;
- Guidewires;
- Balloon Inflation Devices;
- Y Connector Sets;
- Manifolds;
- Connecting tubings;
- Tourniquets / Pressure Bandage;
- Hydrophilic coating guide wires;
- Dose-control syringes;
- Radial Artery Tourniquets;
- Introducer needles.
Company data
Sales volume10-49 Mio US $
Export content> 75%
Number of employees100-499
Foundation2012
Area of businessElectromedical equipment / Medical Technology